Insulin Pen Shortage Ozempic

Reacting to the news that South Africa has run out of insulin pens as global supply shifts to weight-loss drugs, Dr Mohga Kamal-Yanni, Policy co-lead for the People’s Medicines Alliance, said:

“For people living with diabetes in developing countries, access to insulin pens is a matter of life and death. Yet companies have diverted production of these pens to make more profitable medicines like Ozempic. These medicines are too expensive for diabetic patients in developing countries. Clearly there is a profitable market for using these medicines for weight loss, and it seems Novo Nordisk cares more about that than the lives of diabetics.”

/ Ends

Notes
Ozempic is a treatment for diabetes. Obesity is a side effect of it

For media queries, please contact:
Joe Karp-Sawey, Communications consultant at [email protected]